Research ArticleArticle
Long Receptor Residence Time of C26 Contributes to Super Agonist Activity at the Human β2 Adrenoceptor
Elizabeth M. Rosethorne, Michelle E. Bradley, Karolina Gherbi, David A. Sykes, Afrah Sattikar, John D. Wright, Emilie Renard, Alex Trifilieff, Robin A. Fairhurst and Steven J. Charlton
Molecular Pharmacology April 2016, 89 (4) 467-475; DOI: https://doi.org/10.1124/mol.115.101253
Elizabeth M. Rosethorne
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom (E.M.R., K.G., D.A.S., S.J.C.)
Michelle E. Bradley
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom (E.M.R., K.G., D.A.S., S.J.C.)
Karolina Gherbi
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom (E.M.R., K.G., D.A.S., S.J.C.)
David A. Sykes
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom (E.M.R., K.G., D.A.S., S.J.C.)
Afrah Sattikar
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom (E.M.R., K.G., D.A.S., S.J.C.)
John D. Wright
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom (E.M.R., K.G., D.A.S., S.J.C.)
Emilie Renard
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom (E.M.R., K.G., D.A.S., S.J.C.)
Alex Trifilieff
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom (E.M.R., K.G., D.A.S., S.J.C.)
Robin A. Fairhurst
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom (E.M.R., K.G., D.A.S., S.J.C.)
Steven J. Charlton
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom (E.M.R., K.G., D.A.S., S.J.C.)
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Super Agonism at the β2 Adrenoceptor
Elizabeth M. Rosethorne, Michelle E. Bradley, Karolina Gherbi, David A. Sykes, Afrah Sattikar, John D. Wright, Emilie Renard, Alex Trifilieff, Robin A. Fairhurst and Steven J. Charlton
Molecular Pharmacology April 1, 2016, 89 (4) 467-475; DOI: https://doi.org/10.1124/mol.115.101253
Research ArticleArticle
Super Agonism at the β2 Adrenoceptor
Elizabeth M. Rosethorne, Michelle E. Bradley, Karolina Gherbi, David A. Sykes, Afrah Sattikar, John D. Wright, Emilie Renard, Alex Trifilieff, Robin A. Fairhurst and Steven J. Charlton
Molecular Pharmacology April 1, 2016, 89 (4) 467-475; DOI: https://doi.org/10.1124/mol.115.101253
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement